GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Marker Therapeutics
Marker Therapeutics is an oncology company focused on cell therapy. Its stock price represents a venture bet on its scientific platform. The chart reflects high volatility and dependence on clinical trial news.
Share prices of companies in the market segment - Cancer blood
Marker Therapeutics is an oncology company developing T-cell-based cell therapies for the treatment of blood cancers and solid tumors. We've categorized it as "Blood Cancer." The chart below shows how investors view this innovative but high-risk biotech sector.
Broad Market Index - GURU.Markets
Marker Therapeutics is an oncology company developing next-generation T-cell therapy for blood cancers. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Marker shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
MRKR - Daily change in the company's share price Marker Therapeutics
For Marker Therapeutics, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data for its cell therapy and is a critical metric for assessing risk.
Daily change in the price of a set of shares in a market segment - Cancer blood
Marker Therapeutics is a clinical-stage biotech, which implies extreme volatility. The chart below reflects the average daily risk exposure in the immunotherapy sector. It serves as a benchmark for assessing how MRKR's stock fluctuations correspond to the overall industry "nervousness" that persists from report to report.
Daily change in the price of a broad market stock, index - GURU.Markets
Marker Therapeutics is a biotech company developing cell therapy for blood cancer. Its shares are a bet on a scientific breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Marker Therapeutics
Marker Therapeutics' year-to-date performance is a story of next-generation cell therapy development. Its 12-month market cap depends entirely on clinical trial data for its approach using memory T cells. Success could offer a safer and more durable treatment for blood cancer than traditional CAR-T therapies.
Annual dynamics of market capitalization of the market segment - Cancer blood
Marker, as an early-stage biotech company, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cell therapy. Its stock price will reflect investors' speculative belief in the potential of its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Marker Therapeutics is a cutting-edge cell therapy company whose performance is entirely dependent on clinical trial success. Its chart, compared to the market, illustrates how hope for a breakthrough in cancer treatment can create its own reality for stocks, completely ignoring economic cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Marker Therapeutics
Marker Therapeutics is a clinical-stage oncology company developing T-cell therapy. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its flagship programs is a key event, generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Cancer blood
Marker Therapeutics is a biotech company developing a new generation of cell therapy (T-cells) for the treatment of blood cancer. Its approach does not require genetically engineering cells. The graph below shows the dynamics of the biotech sector, where the search for safer and more effective cell therapies continues.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Marker Therapeutics is a biotech company developing cell therapy for blood cancer. Its shares move not in sync with the market, but rather based on the results of clinical trials. The success or failure of a single trial can dramatically change the company's value.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Marker Therapeutics
Marker Therapeutics is developing a new type of cell therapy for cancer. Its weekly stock price is a speculative bet on the success of its unique technology. Clinical news is causing extreme fluctuations.
Weekly dynamics of market capitalization of the market segment - Cancer blood
Marker Therapeutics is developing a cell therapy for blood cancer. The chart helps separate the stock's unique reaction to clinical trial news from the overall sentiment in the oncology sector. Is the weekly price movement specific to Marker or is it an industry trend?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Marker Therapeutics is another biotech company whose stock exists in its own universe, reacting to clinical trial data. The chart clearly demonstrates how its weekly performance is isolated from general market fluctuations, following its own unique scientific trajectory.
Market capitalization of the company, segment and market as a whole
MRKR - Market capitalization of the company Marker Therapeutics
The chart for Marker Therapeutics shows a bet on a new generation of cancer cell therapy. This biotech's market cap reflects investors' faith in its non-genetically modified T-cell technology. This is a highly volatile curve of scientific hopes, typical of the clinical stage.
MRKR - Share of the company's market capitalization Marker Therapeutics within the market segment - Cancer blood
Marker Therapeutics is a biopharmaceutical company developing a new type of cell therapy for blood cancer using memory T-cells. Its market capitalization in this segment reflects the uniqueness of its approach. The company's market capitalization reflects its bet that its therapy will be safer and more durable than existing CAR-T therapies.
Market capitalization of the market segment - Cancer blood
Marker Therapeutics is developing T-cell therapy. How big is this arena? The chart below shows the pulse of the blood cancer treatment sector. Its high volatility reflects both the enormous hopes for the next generation of "living drugs" and the high risks associated with their development.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Marker Therapeutics chart shows how the market values this unique approach to cell-based cancer therapy. The market cap of this company developing unmodified T cells reflects its scientific potential and long road to commercialization. This chart is full of hope for safer and more accessible immunotherapy.
Book value capitalization of the company, segment and market as a whole
MRKR - Book value capitalization of the company Marker Therapeutics
For Marker Therapeutics, a cell therapy company, book value is its tangible foundation: its own cGMP manufacturing facilities for T-cell therapies, its laboratories, and its financial reserves. The chart below shows how the company has invested in building this sophisticated scientific and manufacturing base.
MRKR - Share of the company's book capitalization Marker Therapeutics within the market segment - Cancer blood
Marker Therapeutics is a cell therapy company. Its main assets are its own GMP manufacturing facilities, where it grows and processes T-cells to fight cancer. This facility is the physical heart of its innovative technology. The chart shows the company's control over this unique biotech infrastructure.
Market segment balance sheet capitalization - Cancer blood
Marker Therapeutics is a cell therapy company. Pharmaceuticals, as the chart shows, are capital-intensive. Marker is a prime example. Its business requires the construction of its own highly complex and expensive laboratories and factories to produce cell therapy products.
Book value of all companies included in the broad market index - GURU.Markets
Marker Therapeutics' assets are not drugs, but laboratories and a pilot plant for developing a unique cell therapy that uses unmodified T cells to fight cancer. The book value reflects the material basis for this innovative approach to oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Marker Therapeutics
Marker Therapeutics is developing a T-cell-based cell therapy targeting multiple tumor antigens. Its value lies in this scientific platform. The chart shows how the market perceives its potential for treating blood cancers after transplantation.
Market to book capitalization ratio in a market segment - Cancer blood
Marker Therapeutics is developing cell therapy for the treatment of cancer. Its valuation is based on the potential of its unique platform, which does not require genetic modification of cells. The chart demonstrates the high valuation of this scientific approach by investors.
Market to book capitalization ratio for the market as a whole
Marker Therapeutics is a cancer cell therapy company. Its entire market value is based on the potential of its scientific platform and its hopes of curing patients. This chart illustrates how, in cutting-edge biotech, valuation reflects investors' faith in a future medical revolution.
Debts of the company, segment and market as a whole
MRKR - Company debts Marker Therapeutics
Marker Therapeutics is a biotech company developing cell therapies for the treatment of cancer. This complex and personalized technology requires significant investment in research and production. This chart shows how the company is raising capital to fund its expensive clinical trials and develop its unique platform.
Market segment debts - Cancer blood
Marker Therapeutics is a clinical-stage oncology company developing T-cell-based cell therapy. Its approach differs from traditional CAR-T technologies. Funding for this complex research is entirely dependent on equity capital. This chart shows its cash "margin of safety."
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Marker Therapeutics
Marker Therapeutics is a biotech company working in cancer cell therapy. This chart shows its financial structure. For a company in clinical development, without stable revenue, any debt is a significant risk. Its survival depends on successful trials and the ability to raise equity capital.
Market segment debt to market segment book capitalization - Cancer blood
Marker Therapeutics is a biotech company developing cell therapy for blood cancer. Its approach doesn't require genetic modification of cells, which could be an advantage. The chart shows the overall debt burden in the sector, providing context for assessing how the company finances its unique but capital-intensive clinical research.
Debt to book value of all companies in the market
Marker Therapeutics is a clinical-stage biopharmaceutical company developing cell therapy for blood cancer. This approach is personalized and complex. This chart clearly shows that for such advanced, yet uncommercialized technologies, debt financing is unavailable, and the company relies entirely on investor capital.
P/E of the company, segment and market as a whole
P/E - Marker Therapeutics
For Marker Therapeutics, a company developing cell therapy for cancer, the P/E ratio is not applicable. The company has no revenue, and its valuation on this chart is arbitrary. It is a speculative bet that its unique treatment approach will prove safe and effective in clinical trials.
P/E of the market segment - Cancer blood
Marker Therapeutics is a clinical-stage immuno-oncology company developing a new class of T-cell therapies for the treatment of blood cancers. This chart shows the average valuation for the sector, providing investors with context for assessing the scientific potential and risks associated with Marker's innovative platform.
P/E of the market as a whole
Marker Therapeutics is a biotech company developing cell therapy for cancer. Its valuation is a pure bet on the success of its scientific platform. It has no connection to the general economic cycles depicted by this chart. Marker's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Marker Therapeutics
Marker Therapeutics is a clinical-stage biotech developing a new type of memory T-cell therapy for the treatment of blood cancers. This chart reflects investor expectations for its innovative approach. The valuation is based on the potential to offer a safer and more durable treatment than CAR-T therapy.
%20P%2FE%20Marker%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Marker-Therapeutics&v=1772654173263 "Chart of the company's future (projected) P/E Marker Therapeutics")
Future (projected) P/E of the market segment - Cancer blood
Marker Therapeutics is an immuno-oncology company developing T-cell-based cell therapy for the treatment of blood cancers. Its valuation relative to other biotechs in the field reflects investors' appreciation of its unique approach, which does not require genetic modification of cells. This is a bet on a safer and less expensive treatment method.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772654173276 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
Marker Therapeutics is developing a new type of cell therapy (TCR-T) for the treatment of cancer. This is a complex and highly competitive field of biotechnology. This chart illustrates the overall risk appetite of investors. For companies with innovative but risky platforms like Marker, a positive market environment is important for raising capital for long-term clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772654173291 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Marker Therapeutics
Marker Therapeutics is a biotech company developing a new type of cancer cell therapy based on T cells targeting multiple antigens. The financial trend shown here reflects the costs of clinical trials of this complex and promising technology.
Profit of companies in the market segment - Cancer blood
Marker Therapeutics is an oncology company developing T-cell-based cell therapy for the treatment of blood cancers. This chart reflects the financial health of the hematological oncology sector. It shows whether this cutting-edge field is commercially viable or whether it remains the domain of expensive and risky clinical trials.
Overall market profit
Marker Therapeutics develops cell therapies for the treatment of cancer. This is a complex and innovative field of medicine. As with most clinical-stage biotech companies, for MRKR, the macroeconomic metrics reflected in this chart are irrelevant compared to research results and FDA decisions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Marker Therapeutics
Marker Therapeutics is a biotech company developing cell therapy for blood cancer. Its future profit forecast depends on the success of clinical trials and regulatory approval. This chart shows how analysts assess the potential of its unique approach to cancer treatment.
%20profit%20of%20the%20company%20Marker%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Marker-Therapeutics&v=1772654173376 "Graph of future (projected) profit of the company Marker Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer blood
Marker Therapeutics is developing next-generation cell therapy (based on memory T cells) for the treatment of cancer, particularly after bone marrow transplantation. This chart shows the outlook for the blood cancer sector. It illustrates the hopes for scientific breakthroughs that could offer new treatment options for patients with complex forms of cancer.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772654173395 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
For Marker Therapeutics, a company working in cancer cell therapy, this schedule is important for the investment climate. Optimistic economic forecasts facilitate raising the significant funds needed for clinical trials. During downturns, investors are less risk-averse.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772654173419 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Marker Therapeutics
Marker Therapeutics is developing cell therapy for cancer. With no commercial products, its valuation, as shown in this chart, reflects investors' pure expectations for the success of its clinical trials.
P/S market segment - Cancer blood
Marker Therapeutics is an immuno-oncology company developing a new type of T-cell-based cell therapy for the treatment of blood cancers. This chart shows the average valuation in the oncology sector. It reflects investor expectations for Marker's unique approach, which does not require genetic modification of cells, and its potential for treating leukemia and lymphoma.
P/S of the market as a whole
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing a new generation of T-cell-based cell therapy for the treatment of hematologic cancers. Its valuation reflects the potential of this therapy. This chart contrasts the valuation of speculative biotechs with that of companies with current revenues.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Marker Therapeutics
Marker Therapeutics is developing a T-cell-based cancer therapy. Unlike CAR-T, its approach may be less toxic. The company's valuation is based on the future potential of this technology. The chart shows investors' confidence that its unique treatment will prove effective and carve out a niche in the market.
%20P%2FS%20Marker%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Marker-Therapeutics&v=1772654173542 "The graph of the company's future (projected) P/S Marker Therapeutics")
Future (projected) P/S of the market segment - Cancer blood
Marker Therapeutics is developing a new type of cell-based cancer therapy based on T cells that target multiple tumor cells. This approach could be effective where other immunotherapies fail. This chart shows how investors view the potential of this complex but promising technology.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772654173567 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
This chart reflects expectations for the cell therapy market. For Marker Therapeutics, a company developing T-cell-based therapies, it reflects faith in personalized medicine. Market optimism helps fund complex and individualized cancer treatment approaches that can help patients with limited options.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772654173577 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Marker Therapeutics
Marker Therapeutics is a clinical-stage immuno-oncology company developing a novel cell therapy (TCR-T) for the treatment of hematologic malignancies and solid tumors. This chart reflects grant revenue. Future revenue is dependent on the success of clinical trials and the commercialization of its unique T-cell therapy platform.
Sales of companies in the market segment - Cancer blood
Marker Therapeutics is an immuno-oncology company developing cell therapy based on memory T cells. This graph shows the growth of the blood cancer treatment market. Marker's unique approach does not require genetic modification of cells, which could make the therapy safer and more accessible, offering a new solution in this complex field.
Overall market sales
Marker Therapeutics is an immuno-oncology company developing cell therapy for blood cancer. Its development depends on the success of clinical trials. The overall economic situation, shown in this chart, affects the availability of funding for biotech companies working on innovative treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Marker Therapeutics
Marker Therapeutics is developing a new type of cell-based cancer therapy based on T cells specific to multiple tumor antigens. This approach has the potential to be safer than CAR-T therapy. This timeline reflects analysts' expectations for the success of clinical trials of this innovative oncology platform.
%20sales%20of%20the%20company%20Marker%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Marker-Therapeutics&v=1772654173666 "Schedule of future (projected) sales of the company Marker Therapeutics")
Future (projected) sales of companies in the market segment - Cancer blood
Marker Therapeutics is an immuno-oncology company developing T-cell-based cell therapies for the treatment of blood cancers. This graph highlights expectations for the entire blood cancer sector. It illustrates the significant interest in new cell therapies that could offer treatment options for seriously ill patients.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772654173679 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing T-cell-based cell therapies for the treatment of hematologic malignancies. Its future depends on the success of clinical trials. This graph, reflecting the state of the economy, affects the availability of capital for biotech companies working on personalized cancer treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772654173698 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Marker Therapeutics
Marker Therapeutics is developing a new type of cell therapy for cancer that does not require gene modification. This graph shows the financial status at the clinical trial stage. Negative values represent investments in this innovative platform. Successful research could lead to the development of safer and more affordable immunotherapy.
Market segment marginality - Cancer blood
Marker Therapeutics is a biotech company developing cell therapy for blood cancer. This chart serves as a benchmark for a company in clinical trials. It shows the average profitability in the oncology sector, illustrating the financial potential that could be realized if their therapy is successful and commercialized.
Market marginality as a whole
Marker Therapeutics is a clinical-stage immuno-oncology company developing T-cell-based cell therapy. This overall market profitability graph is irrelevant to the company. Its future depends solely on the results of clinical trials and its ability to demonstrate the efficacy of its approach in cancer treatment.
Employees in the company, segment and market as a whole
Number of employees in the company Marker Therapeutics
Marker Therapeutics is a biotech company developing a new type of cell therapy for cancer. This graph shows a small team of scientists and clinicians focused on advancing their unique technologies through clinical trials. Their number reflects the research-intensive nature of the business.
Share of the company's employees Marker Therapeutics within the market segment - Cancer blood
Marker Therapeutics is developing T-cell therapy that targets multiple tumor antigens simultaneously. This chart shows the percentage of leading immunologists and cell therapy specialists the company attracts to this cutting-edge field of oncology. It reflects its concentration of unique scientific talent to create more effective cancer treatments.
Number of employees in the market segment - Cancer blood
Marker Therapeutics is developing a new type of cancer cell therapy (TCR-T), which may be effective against a wide range of tumors. This graph illustrates how the oncology field is constantly exploring new approaches, necessitating massive investments in research and attracting the best cell biologists and immunologists to create the medicine of the future.
Number of employees in the market as a whole
Marker Therapeutics is a cancer cell therapy company. It's the personalized medicine of the future. This graph depicts today's labor market, but it's companies like Marker that are creating jobs that require a unique combination of medical, biological, and technological skills, creating an elite workforce.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Marker Therapeutics (MRKR)
Marker Therapeutics is a biotech company developing T-cell cancer therapy. This chart is a classic example of intellectual capital valuation. The company's value is based on market expectations for its unique (non-genetically engineered) cell therapy platform. The chart demonstrates the high future value the market is pricing into this research.
%20of%20the%20company%20Marker%20Therapeutics%20(MRKR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Marker-Therapeutics-MRKR&v=1772654174013 "Chart of market capitalization per employee (in thousands of dollars) of the company Marker Therapeutics (MRKR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
Marker Therapeutics is developing cell therapy for blood cancer, a highly specialized area of biotech. The chart shows how investors assess the potential of their scientific platform per scientist. This comparison with the sector allows one to assess how unique and promising their approach is considered.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772654174033 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
Marker Therapeutics is a biopharmaceutical company developing cell therapies for cancer treatment. This chart shows the average market capitalization per employee, highlighting its high appreciation for innovative approaches to medicine.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772654174039 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Marker Therapeutics (MRKR)
Marker Therapeutics is a clinical-stage biotech company developing cell therapies for cancer. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company burns through each scientist in the development of its complex therapy.
%20Chart%20Marker%20Therapeutics%20(MRKR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Marker-Therapeutics-MRKR&v=1772654174049 "Company Profit Per Employee (in thousands of dollars) Chart Marker Therapeutics (MRKR)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
Marker Therapeutics is a biopharmaceutical company developing cell therapy for blood cancer. Its core assets are its unique technology and team of scientists. During the clinical trial stage, this graph will likely show negative earnings per employee, reflecting its high investment in R&D and the norm for innovative companies in this industry.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772654174052 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
Marker Therapeutics (MRKR) is a clinical-stage biotech company developing T-cell therapy for the treatment of blood cancers (leukemia, lymphoma). This is an R&D business. This chart shows the average profitability per employee across the market. For MRKR (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772654174053 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Marker Therapeutics (MRKR)
Marker Therapeutics is a clinical-stage immuno-oncology company developing cell therapies. This chart is a glimpse into the future, reflecting the enormous revenue potential if its unique approach to cancer treatment is successful and approved for widespread use by regulators.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Marker-Therapeutics-MRKR&v=1772654174071 "Sales chart per company employee Marker Therapeutics (MRKR)")
Sales per employee in the market segment - Cancer blood
Marker Therapeutics is a biotech company developing cell therapy (T-cell-based) for the treatment of blood cancer. The company is in the R&D stage. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of Marker's scientific team.
Sales per employee for the market as a whole
Marker Therapeutics is a clinical-stage biotechnology company developing cell therapy (T-cells) for cancer treatment. The company has no commercial products and, therefore, no revenue from them. This metric is currently irrelevant. The company's entire value lies in its R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company Marker Therapeutics (MRKR)
Marker Therapeutics is a biotech company developing cell therapy (T-cells) for the treatment of blood cancer. This is a highly competitive field. This chart shows bets that their approach is outdated or ineffective. "Bears" believe their technology will lose out to more advanced CAR-T therapies, which have already captured this market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Marker-Therapeutics-MRKR&v=1772654174146 "Short Shares Chart for the Company Marker Therapeutics (MRKR)")
Shares shorted by market segment - Cancer blood
Marker Therapeutics is an immuno-oncology company developing cell therapy (T-cell-based) for the treatment of blood cancers that does not require genetic engineering (like CAR-T). This chart reflects the total short position in the cell therapy sector. High values indicate general investor skepticism about the success of clinical trials of new, less-studied cell therapy approaches.
Shares shorted by the overall market
Marker Therapeutics is developing cell therapy (T-cells) to treat blood cancer. This is a complex and expensive biotech. This chart measures general fear. When investors are pessimistic, they are unwilling to take on the "binary" risk of clinical trials. They sell off MRKR shares, fearing the company will be unable to raise capital to complete R&D in a market panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Marker Therapeutics (MRKR)
Marker Therapeutics is developing a cell therapy (T-cells) for blood cancer that promises to be less toxic. It's a clinical-stage biotech. This oscillator measures investor sentiment: it shows when positive trial data leads to "overbought" (above 70) or when delays lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Marker-Therapeutics-MRKR&v=1772654174295 "RSI 14 indicator chart for the company's stock Marker Therapeutics (MRKR)")
RSI 14 Market Segment - Cancer blood
Marker Therapeutics is a biotech company developing cell therapy (T-cell-based) for the treatment of blood cancers (leukemia, lymphoma) following stem cell transplantation. This chart measures the collective excitement in the cell therapy sector. It helps determine whether the entire speculative segment is overheated by expectations.
RSI 14 for the overall market
For Marker Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MRKR (Marker Therapeutics)
Marker Therapeutics is a biotech company developing cell therapy (T-cell-based) for the treatment of blood cancers that does not require genetic engineering. This chart shows the average 12-month forecast of analysts, representing their collective speculative bet on the success of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MRKR-Marker-Therapeutics&v=1772654174441 "A chart showing analyst consensus forecasts for the expected stock price. MRKR (Marker Therapeutics)")
The difference between the consensus estimate and the actual stock price MRKR (Marker Therapeutics)
Marker Therapeutics is a biotech company developing T-cell therapy (not CAR-T) that targets multiple tumor antigens simultaneously. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, reflecting their confidence in this complex oncology platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MRKR-Marker-Therapeutics&v=1772654174448 "A chart showing the difference between the consensus forecast and the actual stock price. MRKR (Marker Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
Marker Therapeutics is a biotech R&D company developing cell therapy (T-cells) for the treatment of blood cancers. This is high-risk R&D. This chart reflects analysts' overall expectations for the entire blood cancer sector. It shows whether experts believe in the success of junior biotechs.
Analysts' consensus forecast for the overall market share price
Marker Therapeutics is a biotech company developing cell therapy (T-cell-based) for the treatment of blood cancer. This chart reflects the overall market "risk appetite." For Marker, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical to attracting the capital needed to fund long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Marker Therapeutics
Marker Therapeutics is a biotech R&D company focused on cell therapy (T-cells). Their signature approach isn't CAR-T, but a multi-antigen approach: they train T-cells to attack multiple tumor targets at once, rather than just one. This chart is a pure indicator of their R&D confidence. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) pipeline.
AKIMA Market Segment Index - Cancer blood
Marker Therapeutics (MRKR) is an immuno-oncology company developing next-generation TCR-T cell therapy. Unlike CAR-T, their cells can recognize multiple targets, potentially addressing the problem of relapse. The chart shows the average index for the segment, helping investors assess how this complex technology compares to the average market.
The AKIM Index for the overall market
Marker Therapeutics is a clinical-stage immuno-oncology company specializing in T-cell therapy (MultiTAA) for cancer treatment. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop critical to funding this specialized scientific platform.
